BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) and SpringWorks Therapeutics Inc., (NASDAQ: SWTX) have...
NASDAQ: ONC
BeiGene Launches LATAM Expansion with New Office in São Paulo, Brazil
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced its first...
BeiGene Marks Topping Off of New Biologics Facility in New Jersey
China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the...
BeiGene Declines Option for Leap Therapeutics’ DKN-01 Development Rights in Asia
US-based Leap Therapeutics Inc. (NASDAQ: LPTX) announced last week that China-based BeiGene Ltd. (HKG: 6160,...
BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4...